PizotifenCAS# 15574-96-6 |
2D Structure
- Lidocaine
Catalog No.:BCC1084
CAS No.:137-58-6
- Mianserin HCl
Catalog No.:BCC1114
CAS No.:21535-47-7
- Loratadine
Catalog No.:BCC1262
CAS No.:79794-75-5
- Bavisant
Catalog No.:BCC1402
CAS No.:929622-08-2
- Bavisant dihydrochloride
Catalog No.:BCC1403
CAS No.:929622-09-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 15574-96-6 | SDF | Download SDF |
PubChem ID | 27400 | Appearance | Powder |
Formula | C19H21NS | M.Wt | 295.44 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 20 mg/mL (67.70 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 4-(4,5-dihydrobenzo[1,2]cyclohepta[3,4-b]thiophen-10-ylidene)-1-methylpiperidine | ||
SMILES | CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1 | ||
Standard InChIKey | FIADGNVRKBPQEU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Pizotifen Dilution Calculator
Pizotifen Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3848 mL | 16.9239 mL | 33.8478 mL | 67.6956 mL | 84.6196 mL |
5 mM | 0.677 mL | 3.3848 mL | 6.7696 mL | 13.5391 mL | 16.9239 mL |
10 mM | 0.3385 mL | 1.6924 mL | 3.3848 mL | 6.7696 mL | 8.462 mL |
50 mM | 0.0677 mL | 0.3385 mL | 0.677 mL | 1.3539 mL | 1.6924 mL |
100 mM | 0.0338 mL | 0.1692 mL | 0.3385 mL | 0.677 mL | 0.8462 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pizotifen(Pizotyline) is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.
- Mecarbinate
Catalog No.:BCC4919
CAS No.:15574-49-9
- Isomagnolone
Catalog No.:BCN1701
CAS No.:155709-41-4
- Simonsinol
Catalog No.:BCN1700
CAS No.:155709-40-3
- Notoginsenoside Ft1
Catalog No.:BCN6434
CAS No.:155683-00-4
- PG-9 maleate
Catalog No.:BCC6779
CAS No.:155649-00-6
- Dehydroaglaiastatin
Catalog No.:BCN1699
CAS No.:155595-93-0
- VUF 10166
Catalog No.:BCC5060
CAS No.:155584-74-0
- Hydroxyfasudil hydrochloride
Catalog No.:BCC1636
CAS No.:155558-32-0
- 3a-Epiburchellin
Catalog No.:BCN7015
CAS No.:155551-61-4
- Alisol G
Catalog No.:BCN3461
CAS No.:155521-46-3
- Alisol F
Catalog No.:BCN3360
CAS No.:155521-45-2
- DIPPA hydrochloride
Catalog No.:BCC6799
CAS No.:155512-52-0
- Peujaponiside
Catalog No.:BCN8261
CAS No.:155740-16-2
- Hierochin D
Catalog No.:BCN1702
CAS No.:155759-02-7
- 4-IBP
Catalog No.:BCC6777
CAS No.:155798-08-6
- 3-beta-O-(cis-p-Coumaroyl)corosolic acid
Catalog No.:BCN1553
CAS No.:155800-17-2
- 25-O-Methylalisol A
Catalog No.:BCN3456
CAS No.:155801-00-6
- 5-O-Methylhierochin D
Catalog No.:BCN4526
CAS No.:155836-29-6
- BW 373U86
Catalog No.:BCC5798
CAS No.:155836-50-3
- RJR-2403
Catalog No.:BCC1901
CAS No.:15585-43-0
- 9,10-Dimethoxycanthin-6-one
Catalog No.:BCN3106
CAS No.:155861-51-1
- LE 135
Catalog No.:BCC7242
CAS No.:155877-83-1
- Gipsoside
Catalog No.:BCN8482
CAS No.:15588-68-8
- Edultin
Catalog No.:BCC8321
CAS No.:15591-75-0
Development of antimigraine transdermal delivery systems of pizotifen malate.[Pubmed:26196273]
Int J Pharm. 2015 Aug 15;492(1-2):223-32.
The aim of this study was to develop and evaluate a transdermal delivery system of Pizotifen malate. Pizotifen is frequently used in the preventive treatment of migraine, but is also indicated in eating disorders. In the course of the project, the effects of chemical enhancers such as ethanol, 1,8-cineole, limonene, azone and different fatty acids (decanoic, decenoic, dodecanoic, linoleic and oleic acids) were determined, first using a Pizotifen solution. Steady state flux, diffusion and partition parameters were estimated by fitting the Scheuplein equation to the data obtained. Among the chemical enhancers studied, decenoic acid showed the highest enhancement activity, which seemed to be due to the length of its alkyl chain and unsaturation at the 9th carbon. The influence of iontophoresis and the involvement of electrotransport in said process was determined. The absorption profile obtained with iontophoresis was similar to that obtained with fatty acids and terpenes, though skin deposition of the drug was lower with the former. Transdermal delivery systems (TDS) of Pizotifen were manufactured by including chemical enhancers, decenoic acid or oleic acid, and were subsequently characterized. When the results obtained with solutions were compared with those obtained with the TDS, a positive enhancement effect was observed with the latter with respect to the partitioning and diffusion of the drug across the skin. Our findings endorse the suitability of our TDS for delivering therapeutic amounts of Pizotifen malate.
Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.[Pubmed:23393546]
J Huntingtons Dis. 2012;1(2):195-210.
BACKGROUND: Huntington's disease (HD) is a dominantly inherited neurodegenerative condition characterized by dysfunction in striatal and cortical neurons. There are currently no approved drugs known to slow the progression of HD. OBJECTIVE: To facilitate the development of therapies for HD, we identified approved drugs that can ameliorate mutant huntingtin-induced toxicity in experimental models of HD. METHODS: A chemical screen was performed in a mouse Hdh(Q111/Q111) striatal cell model of HD. This screen identified a set of structurally related approved drugs (Pizotifen, cyproheptadine, and loxapine) that rescued cell death in this model. Pizotifen was subsequently evaluated in the R6/2 HD mouse model. RESULTS: We found that in striatal Hdh(Q111/Q111) cells, Pizotifen treatment caused transient ERK activation and inhibition of ERK activation prevented rescue of cell death in this model. In the R6/2 HD mouse model, treatment with Pizotifen activated ERK in the striatum, reduced neurodegeneration and significantly enhanced motor performance. CONCLUSIONS: These results suggest that Pizotifen and related approved drugs may provide a basis for developing disease modifying therapeutic interventions for HD.
Efficacy of amitriptyline, pizotifen and propranolol in the prevention of migraine.[Pubmed:23416816]
Mymensingh Med J. 2013 Jan;22(1):93-100.
This intervention study conducted in the Neurology outpatient Department of Mymensingh Medical College Hospital (MMCH) from January 2006 to December 2007 to compare efficacy of amitriptyline, Pizotifen and propranolol in the prophylaxis of migraine. Ninety cases were selected following certain inclusion and exclusion criteria. Result showed that the differences in duration, frequency and severity of attack were reduced in all groups but the differences among the groups were not significant (p>0.05). However, compared with amitriptyline and Pizotifen, the propranolol group needed tablet paracetamol as abortive therapy less frequently which was statistically significant (p<0.05). All the drugs were well tolerated with minimum adverse effects.
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function.[Pubmed:24466319]
PLoS One. 2014 Jan 23;9(1):e87026.
There is considerable interest in defining new agents or targets for antithrombotic purposes. The 5-HT2A receptor is a G-protein coupled receptor (GPCR) expressed on many cell types, and a known therapeutic target for many disease states. This serotonin receptor is also known to regulate platelet function. Thus, in our FDA-approved drug repurposing efforts, we investigated the antiplatelet activity of cyproheptadine and Pizotifen, two antidepressant 5-HT2A Receptor antagonists. Our results revealed that cyproheptadine and Pizotifen reversed serotonin-enhanced ADP-induced platelet aggregation in vitro and ex vivo. And the inhibitory effects of these two agents were found to be similar to that of EMD 281014, a 5-HT2A Receptor antagonist under development. In separate experiments, our studies revealed that these 5-HT2A receptor antagonists have the capacity to reduce serotonin-enhanced ADP-induced elevation in intracellular calcium levels and tyrosine phosphorylation. Using flow cytometry, we also observed that cyproheptadine, Pizotifen, and EMD 281014 inhibited serotonin-enhanced ADP-induced phosphatidylserine (PS) exposure, P-selectin expression, and glycoprotein IIb-IIIa activation. Furthermore, using a carotid artery thrombosis model, these agents prolonged the time for thrombotic occlusion in mice in vivo. Finally, the tail-bleeding time was investigated to assess the effect of cyproheptadine and Pizotifen on hemostasis. Our findings indicated prolonged bleeding time in both cyproheptadine- and Pizotifen-treated mice. Notably, the increases in occlusion and bleeding times associated with these two agents were comparable to that of EMD 281014, and to clopidogrel, a commonly used antiplatelet drug, again, in a fashion comparable to clopidogrel and EMD 281014. Collectively, our data indicate that the antidepressant 5-HT2A antagonists, cyproheptadine and Pizotifen do exert antiplatelet and thromboprotective effects, but similar to clopidogrel and EMD 281014, their use may interfere with normal hemostasis.